Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older.~* Locally advanced or metastatic pancreatic cancer.~* Histologic or cytologic confirmation at diagnosis or recurrence of pancreatic cancer~* Measurable disease (RECIST) criteria. Tumor lesions that are situated in a previously irradiated area are not considered measurable, except if there is radiologically confirmed progression of disease within the radiation fields after radiation was completed.~* Failed gemcitabine chemotherapy as indicated by disease progression ≤ 6 months from last gemcitabine treatment~* Two or less than 2 chemotherapy regimens for recurrent/progressive disease.~* Adequate hepatic function based on laboratory values obtained less than 7 days prior to registration:~  * Total bilirubin \<2.0 mg/dL;~ * AST \< 2 x ULN;~ * AST \< 2 x ULN;~ * Hgb \> 9.0 gm/dL;~ * PT \< ULN;~ * PTT \<ULN;~ * Albumin \> 3.0 gm/dL;~ * Alkaline phosphatase \< 3 x ULN;~ * Absolute granulocyte count \> 1000/uL;~ * Platelet count \> 100,000/uL;~ * Serum creatinine \< 1.2 mg/dL for females; \< 1.4 mg/dL for males.~* ECOG performance status (PS) 0 or 1.~* Ability to provide informed consent.~* Life expectancy 12 weeks or greater.~* Male participants should be willing to provide semen samples at required intervals. Inability of the patient to provide all semen samples does not make the patient ineligible. (EXCEPTION: If the patient has been vasectomized. To be noted in the study file).~* Fertile patients agree to use barrier contraception (condoms plus spermicidal jelly) during the vector infusion period and for six weeks after infusion.~* Accessibility of peripheral or central IV line which is adequate for infusions of investigational agent.~Exclusion Criteria:~* Prior malignancy. (EXCEPTION: Patients who are disease free ≥ 5 years and/or patients with non-melanoma skin cancer, Stage I breast cancer, CIS of cervix)~* Any of the following:~  * Pregnant women;~ * Nursing women;~ * Men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device \[IUD\], or abstinence, etc.). This study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown.~* Patients who are HIV+, HBV+ or HCV+.~* Clinically significant ascites causing symptoms or requiring therapeutic paracentesis.~* Medical, psychiatric, or social conditions that would compromise successful adherence to this protocol.~* Concomitant use of other chemotherapeutic, viral or immunotherapeutic agents is not allowed during the 6-week study period.~* ≤ 4 weeks from radiation therapy of their pancreatic primary or ≤ 2 weeks from palliative radiation therapy to metastatic sites.~* ≤ 4 weeks from prior chemotherapy.~* History of congestive heart failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues